| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 112, No. 6, 1405-1418, 1989
© 1989 Guarantors of Brain
research-article |
EFFECT OF ION CHANNEL BLOCKERS ON IMMUNE RESPONSE AND COURSE OF EXPERIMENTAL ALLERGIC NEURITIS
1Departments of Neurology Karolinska Institutet, Huddinge University Hospital Stockholm, Sweden 2Department of Clinical Neurophysiology, Karolinska Institutet, Huddinge University Hospital Stockholm, Sweden
Correspondence to:
Correspondence to: Dr Tomas Olsson, Department of Neurology, Karolinska Institutet, Huddinge University Hospital, S-141 86 Huddinge, Sweden
The influence of the K+ channel blocker quinidine and the Ca++ channel blocker verapamil on in vivo and in vitro immune responses was tested in experimental allergic neuritis (EAN) of Lewis rats. Daily intraperitoneal injections of 4 mg quinidine produced a significant reduction of neurological deficits in EAN rats, whereas verapamil had no effect. In contrast, both drugs inhibited the in viteo proliferative response of regional lymph node cells to specific antigens of bovine peripheral myelin ad purified rpotein derivatie of tyberculin in a similar dose-dependent manner. Quinidine-treated EAN rats revealed considerably less inflammatory infiltration in target tissue than untreated EAN rats, shown immunohistochemically. Single injections of ion channel blockers into EAN rats did not improve nerve cell functions as measured by electrophysiological recordings of sciatic nerve. It is concluded that the dominant effect of quidinine in vivo is attributed to a reduction of the demyelinating autoimmune process. Hence ion channel blocking drugs can exert immunomodulatory effects, which may have implications for their clinical application.
.
Received July 18, 1988. Revised December 9, 1988. Accepted December 13, 1988.
*Guest scientist from the Clinic for Psychiatry and Neurology, Wilhelm-Pieck University, Rostock, GDR